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Background
IL-15 activates and induces the proliferation of CD8+ T
cells and NK cells. The Cancer Immunotherapy Trials
Network (CITN) is conducting a Phase I, open-label,
dose-escalation study of subcutaneous (SQ) rhIL-15 in
advanced melanoma, renal cell, non-small cell lung and
squamous cell head and neck carcinoma patients. The
primary objective is to determine the maximum toler-
ated dose; secondary objectives include evaluation of
immunological activity defined by increases in circulat-
ing lymphocytes.
Methods
Each cycle consists of 5 daily SQ injections of rhIL15
(E.coli-derived, NCI) administered Monday-Friday for
two weeks, followed by 2 weeks observation. The abso-
lute lymphocyte count is evaluated daily during the 10
days of SQ injection and whole blood flow cytometric
analysis of T and NK cell numbers is conducted on
Days 1 and 11 of each cycle.
Results
Three patients have been enrolled in each of the 0.25, 0.5,
1.0 and 2.0 mcg/kg/dose cohorts (n = 12). Ten patients
have completed 2 or more cycles and two have completed
one. Only one serious adverse event, grade 2 pancreatitis,
was observed in a metastatic melanoma patient and began
3 days after completing Cycle 1 treatment at 2.0 mcg/kg.
Flow cytometric data indicate a consistent increase in the
frequency of CD3-CD56+ NK cell numbers at Day 11
compared to Day 1 of Cycle 1 (mean 3.6-fold increase,
range 0.7-8.1). Notably, the subpopulation of CD56bright
NK cells increased 6.7-fold (mean, range 1.8-17.9).
Increases in CD56+ and CD56bright NK cell frequencies
were less pronounced in Cycle 2 (mean fold-increase = 1.6
and 2.9, respectively) and in subsequent cycles. The per-
centage of CD56+ NK cells among CD45+ cells was
higher on Day 11 (mean = 20, range 9-32%) compared to
Day 1 of Cycle 1 (mean = 8, range 3-22%). Two patients
demonstrated remarkably high percentages of CD56+ NK
cells peaking at 42-43% of CD45+ cells. By marked con-
trast, the frequency of CD8+ T cells was largely unchanged
during Cycle 1 (mean fold-increase = 1.2, range 0.5-2.9)
and subsequent cycles.
Conclusion
SQ rhIL-15 was very well tolerated through the 2 mcg/kg/
dose, associated with an increase in CD56+ NK cells, and
a substantial expansion in the CD56bright NK cell subpopu-
lation. The effect on peripheral blood T cells was surpris-
ingly minimal. The 2 mcg/kg/dose cohort will be
expanded to six patients before dose escalation proceeds.
After defining the optimal dosing regimen, combinations
with appropriate monoclonal antibodies will be of interest.
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